Open-Label Extension of the Phase III Study With Tramiprosate (3APS) in Patients With Mild to Moderate Alzheimer's Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00314912|
Recruitment Status : Unknown
Verified July 2007 by Bellus Health Inc.
Recruitment status was: Active, not recruiting
First Posted : April 17, 2006
Last Update Posted : July 16, 2007
|Condition or disease||Intervention/treatment||Phase|
|Alzheimer's Disease||Drug: Tramiprosate (3APS)||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||650 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||An Open-Label Extension of the Phase III Study CL-758007 With Tramiprosate (3APS) in Patients With Alzheimer's Disease|
|Study Start Date :||May 2006|
- To evaluate the long-term safety of Tramiprosate (3APS).
- To provide additional long-term data on the efficacy of Tramiprosate (3APS).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00314912
|United States, California|
|San Francisco Clinical Research Center|
|San Francisco, California, United States|